Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AESI NASDAQ:CCOI NASDAQ:REGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAESIAtlas Energy Solutions$16.68-2.0%$15.55$7.64▼$20.13$2.13B1.084.14 million shs2.30 million shsCCOICogent Communications$17.76-10.4%$19.71$14.82▼$54.37$992.54M0.851.60 million shs2.00 million shsREGNRegeneron Pharmaceuticals$614.78-1.1%$719.15$476.49▼$821.11$65.71B0.31.01 million shs2.19 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAESIAtlas Energy Solutions-6.35%-12.52%-0.62%+77.27%+36.54%CCOICogent Communications-8.33%+7.89%-18.13%+5.65%-57.61%REGNRegeneron Pharmaceuticals-0.99%-3.28%-15.07%-20.49%+5.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAESIAtlas Energy Solutions$16.68-2.0%$15.55$7.64▼$20.13$2.13B1.084.14 million shs2.30 million shsCCOICogent Communications$17.76-10.4%$19.71$14.82▼$54.37$992.54M0.851.60 million shs2.00 million shsREGNRegeneron Pharmaceuticals$614.78-1.1%$719.15$476.49▼$821.11$65.71B0.31.01 million shs2.19 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAESIAtlas Energy Solutions-6.35%-12.52%-0.62%+77.27%+36.54%CCOICogent Communications-8.33%+7.89%-18.13%+5.65%-57.61%REGNRegeneron Pharmaceuticals-0.99%-3.28%-15.07%-20.49%+5.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAESIAtlas Energy Solutions 2.00Hold$18.5711.35% UpsideCCOICogent Communications 2.18Hold$24.9040.20% UpsideREGNRegeneron Pharmaceuticals 2.70Moderate Buy$792.6528.93% UpsideCurrent Analyst Ratings BreakdownLatest CCOI, AESI, and REGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026CCOICogent Communications JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$22.005/20/2026CCOICogent Communications Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/19/2026CCOICogent Communications CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$22.00 ➝ $20.005/19/2026REGNRegeneron Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$1,057.00 ➝ $875.005/18/2026AESIAtlas Energy Solutions Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$13.00 ➝ $19.005/18/2026REGNRegeneron Pharmaceuticals BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$900.00 ➝ $730.005/18/2026REGNRegeneron Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$796.00 ➝ $778.005/18/2026REGNRegeneron Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$950.00 ➝ $850.005/18/2026REGNRegeneron Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$762.00 ➝ $707.005/18/2026REGNRegeneron Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$800.00 ➝ $700.005/18/2026REGNRegeneron Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$875.00 ➝ $855.00(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAESIAtlas Energy Solutions$1.10B1.90$1.35 per share12.38$9.36 per share1.78CCOICogent Communications$975.77M0.91$1.38 per share12.88($2.08) per share-8.54REGNRegeneron Pharmaceuticals$14.34B4.53$41.51 per share14.81$297.23 per share2.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAESIAtlas Energy Solutions-$50.30M-$0.79N/A47.65N/A-9.29%-7.42%-4.01%8/3/2026 (Estimated)CCOICogent Communications-$182.17M-$3.55N/AN/AN/A-17.53%-842.48%-5.40%8/6/2026 (Estimated)REGNRegeneron Pharmaceuticals$4.50B$41.0414.9814.791.3729.65%13.16%10.17%7/30/2026 (Estimated)Latest CCOI, AESI, and REGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/4/2026Q1 2026CCOICogent Communications-$1.03-$0.83+$0.20-$0.83$241.31 million$239.19 million4/29/2026Q1 2026REGNRegeneron Pharmaceuticals$8.91$9.47+$0.56$6.75$3.48 billion$3.61 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAESIAtlas Energy SolutionsN/AN/AN/AN/A2 YearsCCOICogent Communications$0.080.45%+1.87%N/A 14 YearsREGNRegeneron Pharmaceuticals$3.760.61%N/A9.16%N/ALatest CCOI, AESI, and REGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026REGNRegeneron Pharmaceuticalsquarterly$0.940.58%5/20/20265/20/20266/4/20265/1/2026CCOICogent Communicationsquarterly$0.020.46%5/18/20265/18/20266/2/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAESIAtlas Energy Solutions0.511.170.94CCOICogent CommunicationsN/A1.901.90REGNRegeneron Pharmaceuticals0.063.572.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAESIAtlas Energy Solutions34.59%CCOICogent Communications92.45%REGNRegeneron Pharmaceuticals83.31%Insider OwnershipCompanyInsider OwnershipAESIAtlas Energy Solutions16.40%CCOICogent Communications4.20%REGNRegeneron Pharmaceuticals6.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAESIAtlas Energy Solutions1,511124.91 million104.42 millionOptionableCCOICogent Communications1,83350.08 million47.98 millionOptionableREGNRegeneron Pharmaceuticals15,410105.72 million98.35 millionOptionableCCOI, AESI, and REGN HeadlinesRecent News About These CompaniesRegeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?May 29 at 3:16 PM | finance.yahoo.comRegeneron Expands Into Pulmonary Hypertension With New Phase 2 Trial for REGN13335May 29 at 12:50 PM | tipranks.comRegeneron Steps Into CAR T for Advanced Prostate Cancer With New Phase 1 TrialMay 29 at 12:50 PM | tipranks.comRegeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?May 29 at 12:31 PM | zacks.comNational Pension Service Acquires 82,853 Shares of Regeneron Pharmaceuticals, Inc. $REGNMay 29 at 6:37 AM | marketbeat.comFideuram Asset Management Ireland dac Invests $10.12 Million in Regeneron Pharmaceuticals, Inc. $REGNMay 29 at 4:28 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by Geode Capital Management LLCMay 29 at 3:58 AM | marketbeat.comRegeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus OutbreakMay 28 at 4:00 PM | globenewswire.comRegeneron And Parabilis Target Undruggable Proteins As Valuation Draws InterestMay 28 at 1:39 PM | finance.yahoo.comThese 2 Cheap Biotech Stocks Offer Potential for Low-Beta GrowthMay 28 at 11:04 AM | 247wallst.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGNMay 28 at 10:00 AM | prnewswire.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 28 at 2:06 AM | americanbankingnews.comWhy Apogee Slipped On Its Dupixent-Rivaling Eczema ResultsMay 27 at 6:05 PM | finance.yahoo.comAllstate Corp Has $5.92 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGNMay 27 at 3:09 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGNMay 26 at 4:53 PM | globenewswire.comCanaccord Cuts PT on Regeneron Pharmaceuticals (REGN), Cites a Disappointing EventMay 26 at 9:43 AM | finance.yahoo.comAre Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink?May 26 at 8:10 AM | barchart.comLegal & General Group Plc Sells 27,332 Shares of Regeneron Pharmaceuticals, Inc. $REGNMay 26 at 5:36 AM | marketbeat.comProspera Financial Services Inc Decreases Stake in Regeneron Pharmaceuticals, Inc. $REGNMay 26 at 5:20 AM | marketbeat.comJefferies Financial Group Inc. Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGNMay 26 at 5:20 AM | marketbeat.comRegeneron (REGN) Enters $2.32B Collaboration With Parabilis to Target ‘Undruggable’ ProteinsMay 25, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCOI, AESI, and REGN Company DescriptionsAtlas Energy Solutions NYSE:AESI$16.68 -0.34 (-2.00%) Closing price 03:59 PM EasternExtended Trading$16.68 +0.01 (+0.04%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atlas Energy Solutions Inc. engages in the production, processing, and sale of mesh and sand that are used as a proppant during the well completion process in the Permian Basin of Texas and New Mexico. The company provides transportation and logistics, storage solutions, and contract labor services. It sells its products and services to oil and natural gas exploration and production companies, and oilfield services companies. Atlas Energy Solutions Inc. was founded in 2017 and is headquartered in Austin, Texas.Cogent Communications NASDAQ:CCOI$17.76 -2.06 (-10.39%) Closing price 04:00 PM EasternExtended Trading$17.97 +0.21 (+1.18%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cogent Communications Holdings, Inc., through its subsidiaries, provides high-speed Internet access, private network, and data center colocation space services in North America, Europe, Oceania, South America, and Africa. The company offers on-net Internet access and private network services to law firms, financial services firms, and advertising and marketing firms, as well as heath care providers, educational institutions and other professional services businesses, other Internet service providers, telephone companies, cable television companies, web hosting companies, media service providers, mobile phone operators, content delivery network companies, and commercial content and application service providers. It also provides Internet access and private network services to customers that are not located in buildings directly connected to its network; and on-net services to customers located in buildings that are physically connected to its network. In addition, the company offers off-net services to corporate customers using other carriers' circuits to provide the last mile portion of the link from the customers' premises to the network. Further, it operates data centers that allow its customers to collocate their equipment and access the network. It serves primarily to small and medium-sized businesses, communications service providers, and other bandwidth-intensive organizations. Cogent Communications Holdings, Inc. was founded in 1999 and is headquartered in Washington, the District of Columbia.Regeneron Pharmaceuticals NASDAQ:REGN$614.78 -6.74 (-1.08%) Closing price 04:00 PM EasternExtended Trading$616.12 +1.34 (+0.22%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
